

10 September 2026

Drugs used for respiratory issues and COPD

Q1. How many patients have been treated (for any condition) in the last 4 months (April-July 2026) with:

- Benralizumab 151
- Dupilumab 77
- Omalizumab 10 – 12 on omlyclo
- Reslizumab <5
- Mepolizumab 328
- Tezepelumab 185

Q2. Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age-groups:

- Age 6-11 none
- Age 12-17 none
- Age 18 and above - as above figures

Q3. How many patients have been treated in the last 4 months by the Respiratory Medicine department ONLY with:

- Dupilumab 77
- Omalizumab 10 – 12 on omlyclo
-

Q4. How many patients have been treated in the last 4 months for Chronic Obstructive Pulmonary Disease (COPD) with:

- Dupilumab <5
- Mepolizumab 0

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - Personal Information relating to a third party, as the small numbers involved could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018